Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition containing calcium passage paralysor and B family vitamin and its use

A technology of calcium channel blocker and B vitamins, applied in the field of pharmacy, can solve the problem of not supporting patients with coronary heart disease, and achieve the effects of reducing medical costs, improving market prospects, and improving compliance

Active Publication Date: 2006-08-30
SHENZHEN AUSA PHARMA +1
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Hofmann T discloses that calcium antagonists and their nitrates are used in the treatment of patients with coronary heart disease who are resistant to or contraindicated by beta-blockers, can reduce cardiac symptoms and improve prognosis; high homocysteine ​​levels are a risk of coronary heart disease Factors, supplementation of folic acid or B complex vitamins can reduce homocysteine ​​levels, but this study does not support that reduced homocysteine ​​levels are beneficial to the prognosis of patients with coronary heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing calcium passage paralysor and B family vitamin and its use
  • Medicinal composition containing calcium passage paralysor and B family vitamin and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Preparation of Compound Amlodipine Folic Acid Tablets

[0043] Formula: Amlodipine Besylate 5g

[0044] Folic acid 0.4g

[0045] Lactose 50g

[0046] Microcrystalline Cellulose 50g

[0047] Starch 10g

[0048] Sodium carboxymethyl starch 30g

[0049] 10% ethanol solution of povidone

[0050] Magnesium Stearate Appropriate amount

[0051] Preparation method: crush 5g amlodipine besylate, 0.4g folic acid, 50g lactose, 50g crystal cellulose, and 10g starch, pass through a 120-mesh sieve, mix evenly according to the method of equal addition, and add an appropriate amount of 10% povidone The ethanol solution is made into a soft material, granulated, dried, and granulated, and the granules with a water content of about 3% are evenly mixed with an appropriate amount of magnesium stearate, and pressed into 1000 tablets according to a conventional method.

Embodiment 2

[0052] Example 2 Preparation of Compound Amlodipine Folic Acid Tablets

[0053] Formula: Amlodipine Besylate 5g

[0054] Folic acid 0.8g

[0055] Lactose 50g

[0056] Microcrystalline Cellulose 50g

[0057] Starch 10g

[0058] Sodium carboxymethyl starch 30g

[0059] 10% ethanol solution of povidone

[0060] Magnesium Stearate Appropriate amount

[0061] The preparation method is the same as in Example 1, and each tablet is made to contain 5 mg of amlodipine and 0.8 mg of folic acid.

Embodiment 3

[0062] Example 3 Preparation of Compound Amlodipine Folic Acid Tablets

[0063] Formula: Amlodipine Besylate 5g

[0064] Folic acid 5g

[0065] Lactose 50g

[0066] Microcrystalline Cellulose 50g

[0067] Starch 10g

[0068] Sodium carboxymethyl starch 30g

[0069] 10% ethanol solution of povidone

[0070] Magnesium Stearate Appropriate amount

[0071] The preparation method is the same as in Example 1, and each tablet is made to contain 5 mg of amlodipine besylate and 5 mg of folic acid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composite medicine for improving the curative effect of the antihypertensive medicine containing Ca channel retardant and preventing the complications such as eyeground hemorrhage, angina pectoris, myocardial infarction, cerebral apoplexy, heart failure and kidney failure is composed of Ca channel vetardant or its precursor or its active metabolite or its salt, one or more of vitamins in B family and the pharmacologically acceptable carrier.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing a calcium channel blocker and B vitamins and its use, especially a chemical medicine composition for treating, preventing or delaying hypertension and related diseases, belonging to the field of pharmacy. Background technique [0002] Essential hypertension is one of the most common chronic diseases and is the main cause of serious cardiovascular diseases such as myocardial infarction, stroke, and kidney disease. The prevalence of hypertension in my country is 18.8%, and there are more than 160 million patients at present, and the prevalence of hypertension is increasing rapidly. Elevated blood pressure is an independent risk factor for stroke and coronary heart disease, and elevated blood pressure increases the risk of heart failure and kidney disease. The main purpose of treating hypertensive patients is to minimize the total risk of cardiovascular death and disability. Drugs to lower ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4422A61K31/714A61K9/16A61K9/20A61K9/48A61P9/04A61P9/10A61P9/12A61P3/06A61P3/04A61P3/10A61P13/12
Inventor 陈光亮王琳琳段炎炎李莉徐希平
Owner SHENZHEN AUSA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com